Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease

Beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of Alzheimer’s disease (AD). As a result of complexity of AD, no molecule has been approved since 2002. Idalopirdine, a 5-HT6 receptors antagonist, did not show its e...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of medicinal chemistry 2021-01, Vol.210, p.113059, Article 113059
Hauptverfasser:	Toublet, François-Xavier, Lalut, Julien, Hatat, Bérénice, Lecoutey, Cédric, Davis, Audrey, Since, Marc, Corvaisier, Sophie, Freret, Thomas, Sopková-de Oliveira Santos, Jana, Claeysen, Sylvie, Boulouard, Michel, Dallemagne, Patrick, Rochais, Christophe
Format:	Artikel
Sprache:	eng
Schlagworte:	5-HT6 receptors Alzheimer’s disease Butyrylcholinesterase Chemical Sciences Life Sciences Medicinal Chemistry MTDL Neurobiology Neurons and Cognition Prodrugs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!